Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. (Q53852755)

21 May 2018

title

Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. (English)

1 reference

21 May 2018

author

Joseph L. Evans

series ordinal

1

1 reference

21 May 2018

author name string

Jallal B

series ordinal

2

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 February 1999

1 reference

21 May 2018

Expert Opinion on Investigational Drugs

published in

1 reference

21 May 2018

volume

8

1 reference

21 May 2018

issue

2

1 reference

21 May 2018

page(s)

139-160

1 reference

21 May 2018

Protein tyrosine phosphatases in signal transduction.

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Regulation of growth factor-induced signaling by protein-tyrosine-phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Primary prevention of NIDDM: a practical reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Hyperglycemia and microvascular and macrovascular disease in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Metabolic effects of IGF-I in diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein-tyrosine phosphatases: biological function, structural characteristics, and mechanism of catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein tyrosine phosphatases and neural development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

A thousand and two protein tyrosine phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Receptor protein tyrosine phosphatases: involvement in cell-cell interaction and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

'Zip codes' direct intracellular protein tyrosine phosphatases to the correct cellular 'address'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Phosphotyrosine phosphatases with SH2 domains: regulators of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Enhancing leptin response by preventing SH2-containing phosphatase 2 interaction with Ob receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The protein tyrosine phosphatase SHP-2 negatively regulates ciliary neurotrophic factor induction of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Crystal structure of the tyrosine phosphatase SHP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Identification of p130(cas) as a substrate for the cytosolic protein tyrosine phosphatase PTP-PEST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Insulin signal transduction through protein kinase cascades.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

From receptor to transporter: insulin signalling to glucose transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The insulin signalling system and the IRS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Mechanisms and consequences of activation of protein kinase B/Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

A Grb2-associated docking protein in EGF- and insulin-receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Disruption of IRS-2 causes type 2 diabetes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Csk enhances insulin-stimulated dephosphorylation of focal adhesion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Identification of protein-tyrosine phosphatases prevalent in adipocytes by molecular cloning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The transmembrane protein tyrosine phosphatase alpha dephosphorylates the insulin receptor in intact cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

How to measure insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Selective down-regulation of the insulin receptor signal by protein-tyrosine phosphatases alpha and epsilon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Receptor-like protein-tyrosine phosphatase alpha specifically inhibits insulin-increased prolactin gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

1002 protein phosphatases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein tyrosine phosphatase 1B interacts with the activated insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Expression of dominant negative mutant SHPTP2 attenuates phosphatidylinositol 3'-kinase activity via modulation of phosphorylation of insulin receptor substrate-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Different signaling roles of SHPTP2 in insulin-induced GLUT1 expression and GLUT4 translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Insulin signaling in mice expressing reduced levels of Syp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The ability of a new hypoglycaemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

21 January 2018

Glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Brown adipose tissue, beta 3-adrenergic receptors, and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The role of lipoic acid in the treatment of diabetic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Phosphoinositolglycan-peptides from yeast potently induce metabolic insulin actions in isolated rat adipocytes, cardiomyocytes, and diaphragms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Insulin second messengers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Insulin stimulates the biosynthesis of chiro-inositol-containing phospholipids in a rat fibroblast line expressing the human insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Protein kinase inhibitors: the tyrosine-specific protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

The road less travelled: taming phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Visualization of the cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by x-ray crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Vanadium: a review of the reproductive and developmental toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Nutritional factors that can favorably influence the glucose/insulin system: vanadium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Sequential dephosphorylation of a multiply phosphorylated insulin receptor peptide by protein tyrosine phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

A synthetic peptide derived from a COOH-terminal domain of the insulin receptor specifically enhances insulin receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Phosphonate inhibitors of protein-tyrosine and serine/threonine phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.2.139

21 January 2018

Identifiers

DOI

10.1517/13543784.8.2.139

1 reference

21 May 2018

PubMed ID

15992069

1 reference

21 May 2018